Olanzapine vs risperidone: the most-prescribed atypicals compared

For most of the 2000s, if you walked into a US psychiatric clinic with a new diagnosis of schizophrenia, the prescription you walked out with was probably olanzapine or risperidone. Together they represent two of the most-prescribed atypical antipsychotics ever produced. Both are now generic, both are well-studied, and both have decades of post-marketing data. But they are not interchangeable. The differences — particularly in weight gain and prolactin — often determine which one a patient and prescriber settle on.

Receptor profiles

Both block D2 and 5-HT2A receptors. Olanzapine adds strong H1 (sedation, weight), M1 (dry mouth, constipation), and alpha-1 (orthostatic dizziness) blockade. Risperidone is a more selective dopamine and serotonin antagonist with comparatively less anticholinergic and antihistaminergic activity. The receptor profiles predict the clinical differences.

Efficacy: the trial evidence

Multiple head-to-head trials and the CATIE study compared olanzapine and risperidone directly in schizophrenia. Across these studies, olanzapine showed slightly longer time-to-discontinuation and slightly better symptom control on average. The difference is real but modest — meaningful at the population level, easily eclipsed by individual variation.

Network meta-analyses (Leucht et al., Lancet 2013, available via PubMed) place olanzapine in the top tier and risperidone in the upper-middle tier — closer to risperidone than to clozapine, but consistently slightly ahead.

For acute mania in bipolar disorder, both are effective; olanzapine has slightly stronger evidence for maintenance.

Weight and metabolic effects

This is the biggest practical difference for many patients.

• Olanzapine: average year-one weight gain 5–8 kg, with substantial individual variation. Significant rise in diabetes risk and dyslipidaemia. The American Diabetes Association/APA consensus statement places olanzapine and clozapine in the highest metabolic risk tier.
• Risperidone: average weight gain 2–4 kg. Diabetes risk elevated but less than olanzapine. Metabolic effects more modest overall.

For patients with strong family history of diabetes or who are overweight at baseline, this difference often decides the choice.

Prolactin

This is risperidone's biggest disadvantage. Risperidone (and its metabolite paliperidone) raise prolactin substantially — often more than any other atypical, sometimes more than first-generation drugs. Symptoms can include:

• Sexual dysfunction
• Loss of libido
• Menstrual irregularity
• Galactorrhoea (milk discharge)
• Gynaecomastia (breast enlargement) in men
• Long-term, decreased bone density

Olanzapine raises prolactin much less. For patients particularly sensitive to sexual side effects or for adolescents (where bone density matters), olanzapine is often preferred. See our hyperprolactinaemia guide.

Movement effects (EPS)

Risperidone is a more "typical-like" atypical in this respect. At doses above 6 mg/day, EPS rates rise meaningfully. Olanzapine has very low EPS rates across its dose range. For patients with prior EPS or sensitivity to movement side effects, olanzapine has the advantage.

Sedation

Olanzapine is significantly more sedating, especially during the first weeks. Risperidone is mildly sedating but less so. For patients who cannot afford daytime sedation (working, parenting), risperidone is often more practical.

Dosing

• Olanzapine: 5–20 mg once daily, often at night
• Risperidone: 2–6 mg/day, sometimes split into morning and evening

Risperidone has more dosing-form flexibility (tablets, oral solution, fast-dissolving M-tab).

Long-acting injectable options

Olanzapine has Zyprexa Relprevv (every 2 or 4 weeks), but it requires 3 hours of post-injection clinic monitoring because of post-injection delirium/sedation syndrome — a major logistic constraint. Risperidone has Risperdal Consta (every 2 weeks, requires oral overlap) and the newer Perseris (monthly subcutaneous), and its metabolite paliperidone has the most extensive LAI portfolio of any antipsychotic.

When olanzapine is the better choice

• Severe positive symptoms requiring strong antipsychotic action
• Significant insomnia or agitation accompanying psychosis
• Prior intolerance of EPS on other agents
• Adolescents where prolactin elevation is a particular concern
• Acute mania

When risperidone is the better choice

• Strong family or personal history of diabetes
• Patient who cannot afford weight gain
• Need for an LAI (Risperdal Consta or Perseris)
• Need for daytime alertness
• Cost is a primary factor (both are generic and cheap, but in some markets risperidone is even cheaper)

The bigger picture

Choosing between olanzapine and risperidone is one of the most common decisions in psychiatric practice. Neither is "the right answer." The right answer depends on which side effects you can least afford, what other conditions you have, and how you and your prescriber weigh the trade-offs together.

This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Information is summarised from publicly available FDA labelling and peer-reviewed literature. Always consult your prescribing clinician before starting, stopping, or changing any medication. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.